文献速递产科母胎医学

阿司匹林预防早产和足月子痫前期:系统综述与荟萃分析

Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.
PubMed 文献 · Am J Obstet Gynecol · 2017-11-11

该系统综述与荟萃分析检索1985年至2017年6月文献,纳入16项随机对照试验共18907名参与者,评估阿司匹林预防子痫前期的效果。结果显示阿司匹林与早产子痫前期风险降低相关(RR 0.62,95%CI 0.45-0.87),对足月子痫前期无显著影响(RR 0.92,95%CI 0.70-1.21);早产子痫前期的降低仅限于妊娠≤16周开始且每日剂量≥100 mg的亚组(RR 0.33,95%CI 0.19-0.57)。结论认为阿司匹林仅在妊娠≤16周开始且每日剂量≥100 mg时降低早产子痫前期风险,不降低足月子痫前期风险。

要点

  • 阿司匹林与早产子痫前期风险降低相关(RR 0.62,95%CI 0.45-0.87),对足月子痫前期无显著影响(RR 0.92,95%CI 0.70-1.21)。
  • 早产子痫前期的降低仅限于妊娠≤16周开始且每日剂量≥100 mg的亚组(RR 0.33,95%CI 0.19-0.57)。
  • 最大试验(n=1620)中早产子痫前期RR 0.38(95%CI 0.20-0.72),与5项较小试验(n=639)的RR 0.22(95%CI 0.07-0.66)相似。

核心结论

  • 阿司匹林降低早产子痫前期风险,但不降低足月子痫前期风险,且仅在妊娠≤16周开始且每日剂量≥100 mg时有效。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Cinhal、Embase、Web of Science和Cochrane library从1985年至2017年6月的文献。
  • 纳入16项随机对照试验,共18907名参与者,提供早产和足月子痫前期数据。
  • 8项研究评为质量良好,另8项研究认为质量差或不确定。
  • 采用随机效应模型计算相对风险及其95%置信区间。

主要发现

  • 早产和足月子痫前期在研究间存在高度异质性(I2>50%)。
  • 妊娠≤16周开始且每日剂量≥100 mg的早产子痫前期亚组无 heterogeneity(I2=0%)。
  • 阿司匹林与早产子痫前期风险降低相关(RR 0.62,95%CI 0.45-0.87),对足月子痫前期无显著影响(RR 0.92,95%CI 0.70-1.21)。
  • 早产子痫前期的降低仅限于妊娠≤16周开始且每日剂量≥100 mg的亚组(RR 0.33,95%CI 0.19-0.57),该效应在高质量研究中亦观察到。
  • 最大试验(Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-based Preeclampsia Prevention,n=1620)中早产子痫前期RR 0.38(95%CI 0.20-0.72),与5项较小试验(n=639)的RR 0.22(95%CI 0.07-0.66)相似。

局限性

  • 早产和足月子痫前期在研究间存在高度异质性(I2>50%)。
  • 8项研究认为质量差或不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE DATA: Metaanalyses of randomized controlled trials have reported contradictory results about the effect of aspirin in the prevention of preeclampsia, both in terms of the gestational age at the onset of treatment and the dose of the drug. The controversy may be resolved by a metaanalysis that includes several recently published trials and particularly the large Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-based Preeclampsia Prevention trial and by examination of whether there is a difference of the effect of aspirin on preterm vs term preeclampsia. STUDY: We performed a systematic review and metaanalysis that evaluated the prophylactic effect of aspirin during pregnancy. STUDY APPRAISAL AND SYNTHESIS METHODS: We completed a literature search through PubMed, Cinhal, Embase, Web of Science, and Cochrane library from 1985 to June 2017. Relative risks with random effect were calculated with their 95% confidence intervals. RESULTS: Sixteen trials that included 18,907 participants provided data for preterm and term preeclampsia. Eight of the included studies were evaluated as being of good quality, and the other 8 studies were deemed to be of poor or uncertain quality. There was high heterogeneity within studies (I2 >50%) for preterm and term preeclampsia, but no heterogeneity was found in the subgroup of preterm preeclampsia when the onset of treatment was ≤16 weeks of gestation and the daily dose of aspirin was ≥100 mg (I2=0%). Administration of aspirin was associated with reduction in the risk of preterm preeclampsia (relative risk, 0.62; 95% confidence interval, 0.45-0.87), but there was no significant effect on term preeclampsia (relative risk, 0.92; 95% confidence interval, 0.70-1.21). The reduction in preterm preeclampsia was confined to the subgroup in which aspirin was initiated at ≤16 weeks of gestation and at a daily dose of ≥100 mg (relative risk, 0.33; 95% confidence interval, 0.19-0.57). This effect was also observed in the high-quality studies. The reduction in preterm preeclampsia that was observed in the largest trial (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-based Preeclampsia Prevention; n=1620; relative risk, 0.38; 95% confidence interval, 0.20-0.72) was similar to that in the 5 smaller trials in which aspirin was initiated at ≤16 weeks of gestation and at a daily dose of ≥100 mg (n=639; relative risk, 0.22; 95% confidence interval, 0.07-0.66). CONCLUSION: Aspirin reduces the risk of preterm preeclampsia, but not term preeclampsia, and only when it is initiated at ≤16 weeks of gestation and at a daily dose of ≥100 mg.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Roberge S, Bujold E, Nicolaides KH, et al. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2017. PMID: 29138036. doi:10.1016/j.ajog.2017.11.561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。